Relay Therapeutics Upsizes ATM Program to $463M, Adding $213M in New Capacity
RLAY has more than doubled off its 52-week low of $3.025.
Summary
Relay Therapeutics upsized its ATM program by $213 million to a total of $463 million, providing additional financial flexibility following positive clinical data and a strong cash position.
Key Events · Financing and Capital Events · RLAY
-
ATM Program Upsized by $213M
Amendment No. 1 to the Sales Agreement with TD Cowen adds $212,978,049 in new capacity, bringing the total ATM program to $463 million. Through August 3, 2026, 16,006,569 shares had been sold under the original program, leaving $87 million before the amendment.
-
Financial Impact
At the assumed offering price of $18.83 per share (July 31, 2026 close), the new capacity represents approximately 11.3 million additional shares, or about 5.2% of outstanding shares. The company's net tangible book value per share would increase from $3.89 to $4.61, but new investors would experience immediate dilution of $14.22 per share.
-
Use of Proceeds
Proceeds will fund research and clinical development of current or additional pipeline candidates, working capital, and general corporate purposes. The company reported $911 million in cash as of the same-day 8-K, extending runway into 2029.
-
Sales Agent and Commission
TD Cowen will serve as sales agent, receiving a commission of up to 3.0% of gross proceeds. Sales will be made at market prices on Nasdaq under the ticker RLAY.
Analysis · RLAY · Life Sciences
Relay Therapeutics amended its at-the-market (ATM) sales agreement with TD Cowen, adding $213 million in new capacity to the existing program. The company had already sold $126 million of the original $300 million program, leaving $87 million before this amendment. The upsizing brings the total ATM capacity to $463 million. While ATM programs are dilutive by nature, the company's strong cash position ($911 million as of the same-day 8-K) and recent positive clinical data for zovegalisib suggest this is opportunistic capital raising rather than distress financing. The 3% commission to TD Cowen is standard for such programs.
At the time of this filing, RLAY was trading at $19.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $3.03 to $20.79. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.